The long-term efficacy and tolerability of nisoldipine in patients with mild-to-moderate hypertension

Current Therapeutic Research - Clinical and Experimental

Volumn 58, Issue 3, 1997, Pages 187-199

  Seedat, Yackoob Kassim ^a  

^a UNIVERSITY OF NATAL   (South Africa)

Author keywords

blood pressure; hypertension; long term treatment; nisoldipine coat core

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; NISOLDIPINE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; ESSENTIAL HYPERTENSION; FEMALE; HEADACHE; HEART INFARCTION; HEART RATE; HUMAN; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STANDING; SYSTOLIC BLOOD PRESSURE; TABLET;

EID: 0030889605     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(97)80014-8     Document Type: Article

References (33)

1. Rosenthal T, Frohlich ED. Nisoldipine in the treatment of hypertension. Adv Ther. 1993; 10:151-156.
2. Mitchell J, Frishman W, Heiman M. Nisoldipine: A new dihydropyridine calcium-channel blocker. J Clin Pharmacol. 1993;33:46-52.
3. Parra-Carrillo JZ, Calvo-Vargas CG, Napoles-Rodriguez F, et al. Efficacy and safety of nisoldipine in mild to moderate hypertension. Invest Med Int. 1994;21:112-121.
4. Ottosson AM, Karlberg BE. Immediate and long-term cardiovascular effects of nisoldipine in normotensive and hypertensive subjects. J Drug Dev. 1991;3:179-188.
5. Fujii Y, Hattori S, Nagami K, et al. The hypertensive effect of nisoldipine: 24-hour blood pressure profile and serial alterations of renal and hormonal function. Curr Ther Res. 1994;55:93-101.
6. Blau A, Herzog D, Schechter, Eliahov HE. Effect of nisoldipine on ambulatory blood pressure under 24-hour noninvasive monitoring. Isr J Med Sci. 1992;28:688-693.
7. Rosenfeld JB, Zabludowski J. The efficacy and tolerability of nifedipine (NIF) and nisoldipine (NIS) both alone and combined with a beta-blocker in patients with essential hypertension: A multicenter, parallel-group study. J Clin Pharmacol. 1989;29:1013-1016.
8. Rosendorff C, Goodman C. Double-blind double-dummy crossover study of the efficacy and safety of nisoldipine (BAYk5552) versus nifedipine. Curr Ther Res. 1985;37:912-920.
9. Friedel HA, Sorkin EM. Nisoldipine: A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders. Drugs. 1988;36:682-731.
10. Schall R, Muller FO, Groenwoud C, et al. Single-dose and steady-state pharmacokinetic and pharmacodynamic profiles of nisoldipine coat-core tablets in healthy young, healthy elderly, and elderly hypertensive volunteers. Drug Invest. 1994;8:21-30.
11. Zannad F. Clinical pharmacology of nisoldipine coat core. Am J Cardiol. 1995;75:41E-45E.
12. Lewis BS. Efficacy and safety of nisoldipine coat core in the management of angina pectoris, systemic hypertension, and ischemic heart ventricular dysfunction. Am J Cardiol. 1995;75(Suppl):46E-53E.
13. Lasseter KC, Muller FO, Garrett BN, et al. Pharmacokinetics, pharmacodynamics and clinical utility of nisoldipine coat core in the treatment of essential hypertension. Cardiovasc Rev Rep. 1996;17:28-46.
14. Fodor JG. Comparative efficacy and tolerability of nisoldipine CC and hydrochlorothiazide in mild to moderate hypertension. Can J Cardiol. In press.
15. Marazzi P. A study to demonstrate the equivalence in efficacy and safety of once daily nisoldipine CC and amlodipine in the treatment of mild to moderate hypertension. Acta Ther. 1996;22:23-35.
16. Opie LH, Muller FO, Myburgh DP, et al. Efficacy and tolerability of nisoldipine CC in the treatment of essential hypertension. Am J Hypertens. In press.
17. Ruddy TD, Fodor JG, Sami MH. The efficacy and tolerability of once-daily nisoldipine coat-core versus lisinopril in the treatment of mild to moderate hypertension. Cardiovasc Drugs Ther. In press.
18. Murray TS. A study to investigate the comparative efficacy and tolerability of nisoldipine coat-core and atenolol in the treatment of mild to moderate hypertension. Br J Clin Pract. 1996;50:368, 370-372.
19. Sareli P. Nisoldipine CC in black patients with severe hypertension: Effects on ambulatory blood pressure profiles and left ventricular mass. Presented at Nisoldipine CC investigators meeting; May 10-11, 1996; Wiesbaden, Germany. Cardiology. 1997;88:51.
20. Rodriguez-Manas L. Efficacy, safety and quality of life with nisoldipine CC and enalapril in elderly patients with mild-to-moderate hypertension. Presented at Nisoldipine CC investigators meeting; May 10-11, 1996, Wiesbaden, Germany. In press.
21. Cruickshank JM, McAinsh J. Patient compliance on taking cardiovascular drug therapy. Acta Ther. 1992;18:53-60.
22. Onesti G. Treatment of mild hypertension and the problem of compliance. Curr Med Res Opin. 1983;8(Suppl 3):77-80.
23. Moore MA. Improving compliance with anti-hypertensive therapy. Am Fam Phys. 1988; 37:142-148.
24. Sneddon PL, Farral DL. Medication compliance in elderly patients. Pharm J. 1989; R18-R20.
25. De Divitis O, et al. Dose titration and long-term treatment with nisoldipine in hypertension. Presented at the Nisoldipine Workshop, October 16-18, 1986, Luxembourg.
26. Lund-Johansen P, Omvik P, Haugland H. Acute and chronic hemodynamic effects of nisoldipine in essential hypertension at rest and during exercise. Acta Med Scand. 1986;4(Suppl 714):183-186.
27. Baumann J. Non-blind, long term, multicenter study of the safety, tolerability and efficacy of once daily doses of nisoldipine 10, 20, 30 and 40 mg coat-core tablets in hypertensive patients. 1992. Study No 675; data on file, Zeneca Pharmaceuticals, Macclesfield, United Kingdom.
28. Murray TS. The long-term safety and efficacy of nisoldipine coat-core in the treatment of mild to moderate hypertension. 1992. Study No 690; data on file, Zeneca Pharmaceuticals, Macclesfield, United Kingdom.
29. Opie LH, Myburgh DP, Sareli P, Seedat YK. South African multi-centre continuation study to assess the long term safety, tolerability and continued antihypertensive response to nisoldipine coat-core using an open, flexible dosage regimen for up to one year. 1993. Study No 689; data on file, Zeneca Pharmaceuticals, Macclesfield, United Kingdom.
30. Nolan L, O'Malley K. Prescreening for the elderly: Part I. Sensitivity of the elderly to adverse drug reactions. J Am Geriatr Soc. 1988;36:142-149.
31. Lamy PP. Adverse drug effects. Clin Geriatr Med. 1990;6:293-307.
32. Seibold H, Hoher M. Elderly patients benefit from calcium antagonist therapy. Geriatr Forsch. 1994;4:137-140.
33. Davidsson GK, Smithard DJ, Edwards JS, Davidson C. A comparison of once daily versus twice daily nisoldipine as monotherapy in patients over 65 years of age. Clin Trials Meta-Analys. 1994;29:103-111.